Nature Communications (Sep 2023)
MYC Deregulation and PTEN Loss Model Tumor and Stromal Heterogeneity of Aggressive Triple-Negative Breast Cancer
- Zinab O. Doha,
- Xiaoyan Wang,
- Nicholas L. Calistri,
- Jennifer Eng,
- Colin J. Daniel,
- Luke Ternes,
- Eun Na Kim,
- Carl Pelz,
- Michael Munks,
- Courtney Betts,
- Sunjong Kwon,
- Elmar Bucher,
- Xi Li,
- Trent Waugh,
- Zuzana Tatarova,
- Dylan Blumberg,
- Aaron Ko,
- Nell Kirchberger,
- Jennifer A. Pietenpol,
- Melinda E. Sanders,
- Ellen M. Langer,
- Mu-Shui Dai,
- Gordon Mills,
- Koei Chin,
- Young Hwan Chang,
- Lisa M. Coussens,
- Joe W. Gray,
- Laura M. Heiser,
- Rosalie C. Sears
Affiliations
- Zinab O. Doha
- Department of Molecular and Medical Genetics, Oregon Health & Science University
- Xiaoyan Wang
- Department of Molecular and Medical Genetics, Oregon Health & Science University
- Nicholas L. Calistri
- Department of Biomedical Engineering, Oregon Health & Science University
- Jennifer Eng
- Department of Molecular and Medical Genetics, Oregon Health & Science University
- Colin J. Daniel
- Department of Molecular and Medical Genetics, Oregon Health & Science University
- Luke Ternes
- Department of Biomedical Engineering, Oregon Health & Science University
- Eun Na Kim
- Department of Biomedical Engineering, Oregon Health & Science University
- Carl Pelz
- Department of Molecular and Medical Genetics, Oregon Health & Science University
- Michael Munks
- Brenden-Colson Center for Pancreatic Care, Oregon Health & Science University
- Courtney Betts
- Department of Cell, Developmental & Cancer Biology, Oregon Health and Science University
- Sunjong Kwon
- Department of Biomedical Engineering, Oregon Health & Science University
- Elmar Bucher
- Department of Biomedical Engineering, Oregon Health & Science University
- Xi Li
- Division of Oncologic Sciences, Oregon Health and Science University
- Trent Waugh
- Department of Molecular and Medical Genetics, Oregon Health & Science University
- Zuzana Tatarova
- Department of Biomedical Engineering, Oregon Health & Science University
- Dylan Blumberg
- Department of Biomedical Engineering, Oregon Health & Science University
- Aaron Ko
- Department of Molecular Microbiology and Immunology, Oregon Health and Science University
- Nell Kirchberger
- Department of Cell, Developmental & Cancer Biology, Oregon Health and Science University
- Jennifer A. Pietenpol
- Department of Biochemistry, Vanderbilt University Medical Center
- Melinda E. Sanders
- Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center
- Ellen M. Langer
- Department of Molecular and Medical Genetics, Oregon Health & Science University
- Mu-Shui Dai
- Department of Molecular and Medical Genetics, Oregon Health & Science University
- Gordon Mills
- Brenden-Colson Center for Pancreatic Care, Oregon Health & Science University
- Koei Chin
- Department of Biomedical Engineering, Oregon Health & Science University
- Young Hwan Chang
- Department of Biomedical Engineering, Oregon Health & Science University
- Lisa M. Coussens
- Brenden-Colson Center for Pancreatic Care, Oregon Health & Science University
- Joe W. Gray
- Department of Biomedical Engineering, Oregon Health & Science University
- Laura M. Heiser
- Department of Biomedical Engineering, Oregon Health & Science University
- Rosalie C. Sears
- Department of Molecular and Medical Genetics, Oregon Health & Science University
- DOI
- https://doi.org/10.1038/s41467-023-40841-6
- Journal volume & issue
-
Vol. 14,
no. 1
pp. 1 – 21
Abstract
Abstract Triple-negative breast cancer (TNBC) patients have a poor prognosis and few treatment options. Mouse models of TNBC are important for development of new therapies, however, few mouse models represent the complexity of TNBC. Here, we develop a female TNBC murine model by mimicking two common TNBC mutations with high co-occurrence: amplification of the oncogene MYC and deletion of the tumor suppressor PTEN. This Myc;Ptenfl model develops heterogeneous triple-negative mammary tumors that display histological and molecular features commonly found in human TNBC. Our research involves deep molecular and spatial analyses on Myc;Ptenfl tumors including bulk and single-cell RNA-sequencing, and multiplex tissue-imaging. Through comparison with human TNBC, we demonstrate that this genetic mouse model develops mammary tumors with differential survival and therapeutic responses that closely resemble the inter- and intra-tumoral and microenvironmental heterogeneity of human TNBC, providing a pre-clinical tool for assessing the spectrum of patient TNBC biology and drug response.